Know Cancer

or
forgot password

Phase1/1b Clinical Trial of E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma


Phase 1
20 Years
79 Years
Open (Enrolling)
Both
Peripheral T-Cell Lymphoma

Thank you

Trial Information

Phase1/1b Clinical Trial of E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma

Inclusion Criteria


lnclusion Criteria:

- Male and female patients 20 to <80 years of age at the time of informed consent

- Patients histologically or cytologically diagnosed to have peripheral T -cell
lymphoma

- Patients with a history of chemotherapy (including PUVA and retinoid) that resulted
in relapse, recurrence and treatment resistance (just for the administration of E7777
alone)

- Patients subject to CHOP therapy and without a history of prior treatment with
anthracycline or anthraquinone anticancer drugs (just for the administration of E7777
in combination with CHOP therapy)

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1

- No carry-over of beneficial or adverse effects of the prior treatment that may affect
the safety evaluation of the investigational drug (excluding Grade 1 neuropathy and
alopecia)

Exclusion Criteria:

Brain metastasis with clinical symptoms which requires treatment

Serious systemic infection requiring intensive treatment

Serious complications or histories

History of hypersensitivity to protein therapeutics

Known to be positive for HIV antibody, HCV antibody, or HBs antigen

History of malignancy other than peripheral T-cell lymphoma and less than five years have
elapsed since the last remission

Patients who have undergone allogeneic hematopoietic stem cell transplantation

Patients with a relapse within 6 months after autologous hematopoietic stem-cell
transplantation

Type of Study:

Interventional

Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Maximum Tolerated Dose (MTD)

Outcome Time Frame:

3 Weeks

Safety Issue:

Yes

Principal Investigator

Tadashi Nakanishi

Investigator Role:

Study Director

Investigator Affiliation:

Eisai Co., Ltd.

Authority:

Japan: Ministry of Health, Labor and Welfare

Study ID:

E7777-J081-101

NCT ID:

NCT01401530

Start Date:

July 2011

Completion Date:

August 2013

Related Keywords:

  • Peripheral T-cell Lymphoma
  • Neoplasms
  • Neoplasms by Histologic Type
  • Lymphoma
  • Non-Hodgkin
  • T- Cell
  • Lymphatic Diseases
  • Lymphoproliferative Disorders
  • lmmune System Diseases
  • lmmunoproliferative Disorders
  • Lymphoma
  • Lymphoma, T-Cell
  • Lymphoma, T-Cell, Peripheral

Name

Location